R&D for development of new drugs for neglected diseases in India
by Sudip Chaudhuri
International Journal of Technology and Globalisation (IJTG), Vol. 5, No. 1/2, 2010

Abstract: The world pharmaceutical industry dominated by multinational corporations has neglected research for drugs for diseases of poor countries. Introduction of stronger patent protection in India after World Trade Organization's TRIPS agreement has failed to rectify this deficiency despite the substantial increase in R&D activity. In the light of the experience of the Indian private sector and the public-private partnerships initiated in India for the development of new drugs, the paper explores some policy options and suggests the expansion of public-private partnerships to include organisations from other innovative developing countries such as Brazil and China.

Online publication date: Tue, 15-Jun-2010

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology and Globalisation (IJTG):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com